JP2009535425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535425A5 JP2009535425A5 JP2009510039A JP2009510039A JP2009535425A5 JP 2009535425 A5 JP2009535425 A5 JP 2009535425A5 JP 2009510039 A JP2009510039 A JP 2009510039A JP 2009510039 A JP2009510039 A JP 2009510039A JP 2009535425 A5 JP2009535425 A5 JP 2009535425A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diabetes
- medicament according
- micromolar
- metabolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79722806P | 2006-05-03 | 2006-05-03 | |
| PCT/US2007/067971 WO2007131005A2 (en) | 2006-05-03 | 2007-05-02 | Use of organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535425A JP2009535425A (ja) | 2009-10-01 |
| JP2009535425A5 true JP2009535425A5 (https=) | 2010-06-24 |
Family
ID=38477124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510039A Pending JP2009535425A (ja) | 2006-05-03 | 2007-05-02 | 有機化合物の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090281191A1 (https=) |
| EP (1) | EP2015777B1 (https=) |
| JP (1) | JP2009535425A (https=) |
| KR (1) | KR20090005137A (https=) |
| CN (1) | CN101432024A (https=) |
| AT (1) | ATE477819T1 (https=) |
| AU (1) | AU2007248112A1 (https=) |
| BR (1) | BRPI0711174A2 (https=) |
| CA (1) | CA2649701A1 (https=) |
| DE (1) | DE602007008553D1 (https=) |
| MX (1) | MX2008014008A (https=) |
| RU (1) | RU2008147269A (https=) |
| WO (1) | WO2007131005A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2571875A4 (en) | 2010-05-14 | 2013-10-30 | Dana Farber Cancer Inst Inc | CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| US8962546B2 (en) * | 2011-03-01 | 2015-02-24 | Salk Institute For Biological Studies | Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| WO2014205045A1 (en) * | 2013-06-18 | 2014-12-24 | Downes, Michael | Methods of treating muscular dystrophy |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| CN105940005A (zh) | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| EP3122872B1 (en) | 2014-03-27 | 2019-07-03 | The Salk Institute for Biological Studies | Compositions and methods for treating type 1 and type 2 diabetes and related disorders |
| CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| AU2016225076B2 (en) | 2015-02-27 | 2018-09-13 | Salk Institute For Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| WO2017053084A1 (en) * | 2015-09-25 | 2017-03-30 | Salk Institute For Biological Studies | Estrogen related receptor gamma (erry) enhances and maintains brown fat thermogenic capacity |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| US11760977B2 (en) | 2016-05-25 | 2023-09-19 | Salk Institute For Biological Studies | Compositions and methods for organoid generation and disease modeling |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1525323B1 (en) * | 2001-11-09 | 2015-01-21 | Dana-Farber Cancer Institute, Inc. | Pgc-1beta, a novel pgc-1 homologue and uses therefor |
| WO2004015415A1 (ja) * | 2002-08-08 | 2004-02-19 | Japan Science And Technology Agency | 薬剤スクリーニング方法 |
| US20050074765A1 (en) * | 2002-10-16 | 2005-04-07 | Blanchard Steven G. | Methods for identifying and using modulators of estrogen related receptor gamma |
| WO2006130503A2 (en) * | 2005-05-27 | 2006-12-07 | Janssen Pharmaceutica N.V. | Errϝ peptide fragment complexes and uses thereof in drug discovery |
-
2007
- 2007-05-02 BR BRPI0711174-6A patent/BRPI0711174A2/pt not_active IP Right Cessation
- 2007-05-02 KR KR1020087026812A patent/KR20090005137A/ko not_active Withdrawn
- 2007-05-02 EP EP07783060A patent/EP2015777B1/en not_active Revoked
- 2007-05-02 CA CA002649701A patent/CA2649701A1/en not_active Abandoned
- 2007-05-02 DE DE602007008553T patent/DE602007008553D1/de active Active
- 2007-05-02 CN CNA2007800155975A patent/CN101432024A/zh active Pending
- 2007-05-02 RU RU2008147269/14A patent/RU2008147269A/ru not_active Application Discontinuation
- 2007-05-02 MX MX2008014008A patent/MX2008014008A/es not_active Application Discontinuation
- 2007-05-02 AU AU2007248112A patent/AU2007248112A1/en not_active Abandoned
- 2007-05-02 WO PCT/US2007/067971 patent/WO2007131005A2/en not_active Ceased
- 2007-05-02 US US12/299,256 patent/US20090281191A1/en not_active Abandoned
- 2007-05-02 AT AT07783060T patent/ATE477819T1/de not_active IP Right Cessation
- 2007-05-02 JP JP2009510039A patent/JP2009535425A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535425A5 (https=) | ||
| Vichayanrat et al. | Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients | |
| Koran et al. | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder | |
| Imam et al. | Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs | |
| Biederman et al. | A Comparison of Once-Daily and Divided Doses of Modafinil in Children With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. | |
| Khosravan et al. | The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase | |
| Marre et al. | Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients | |
| Hattersley | Molecular genetics goes to the diabetes clinic | |
| Mahmood et al. | Prescription pattern analysis of antidiabetic drugs in diabetes mellitus and associated comorbidities | |
| Tatsuo et al. | A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study | |
| US20240277732A1 (en) | Compositions and methods for treating brain-gut disorders | |
| Ji et al. | Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study | |
| Van Gaal et al. | Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes | |
| KR102311915B1 (ko) | 만성 신장병의 진행 억제 또는 개선제 | |
| Kaneko | Treatment for nocturnal enuresis: the current state in Japan | |
| Lee et al. | Comparison of age of onset and frequency of diabetic complications in the very elderly patients with type 2 diabetes | |
| JP2007500230A (ja) | アルツハイマー病の発症の危険性を治療、検出、及び減少させるための方法及び物質 | |
| Conravey et al. | Myotonia congenita and myotonic dystrophy: surveillance and management | |
| Chien et al. | Effect of sitagliptin as add-on therapy in elderly type 2 diabetes patients with inadequate glycemic control in Taiwan | |
| US20140329844A1 (en) | Method of restoring the incretin effect | |
| US20210315907A1 (en) | Compositions and methods for treating brain-gut disorders | |
| Taki et al. | Postmarketing study of nateglinide in Japan: treatment of medication-naive patients with type 2 diabetes | |
| Letha et al. | Permanent neonatal diabetes due to KCNJ11 gene mutation | |
| Yasuda et al. | Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjögren’s syndrome | |
| Sharma | Diabetes mellitus: an overview |